708 Quince Orchard Road
BeneVir Biopharm, Inc., is a portfolio company within Pansend Life Sciences, a subsidiary of HC2 Holdings, Inc. Its offices and laboratories are located in Gaithersburg, MD, which is part of the BioHealth Capital Region. BeneVir is developing a platform of oncolytic immunotherapies based on T-Stealth Technology, which promotes the persistence and efficacy of oncolytic immunotherapies in advanced tumors.
Founder and CEO: Matthew?Mulvey
Founder and COO: Katherine?Sacksteder
Tweets by BeneVir
6 articles with BeneVir
Heidelberg, Germany-based Boehringer Ingelheim has exercised its option to buy an EMBL Ventures portfolio company, ViraTherapeutics. This follows a collaboration and option deal inked between the two companies in August 2016.
Just about every week has plenty of exciting news in the biopharmaceutical industry, and this week was no different. Here’s a brief look back at some of our top stories.
While the biopharma industry awaits news of an acquisition of Shire by Takeda Pharmaceuticals, it’s a good time to take a look back at the bigger deals so far this year.
Janssen Strikes Deal to Acquire BeneVir and its Oncolytic Virus Platform in Deal Worth Up to $1 B...
5/2/2018Shares of HC2 Holdings, Inc. skyrocketed more than 51 percent in premarket trading today after Janssen Biotech Inc announced it was acquiring Rockville, Maryland-based BeneVir Biopharm, Inc., a subsidiary of HC2 in a deal that could be worth more than $1 billion.
Janssen Biotech, Inc. announced that it has entered into a definitive agreement under which it will acquire BeneVir Biopharm, Inc. (BeneVir), a privately-held, biopharmaceutical company specializing in the development of oncolytic immunotherapies.
Benevir Biopharm Granted Patent Protecting Lead Oncolytic Immunotherapy Stealth-1H And Other Platform Assets